Nakanoshima Qross Global Life Sciences Cluster vol.3 Japan–US Innovation Bridge
About the event
Nakanoshima Qross Global Life Sciences Cluster vol.3 Japan–US Innovation Bridge • Japanese follows English A Special Program Connecting Global Startups, Investment Communities, and Business Opportunities Building on the growing interest and opportunities for exchange generated by Expo 2025 Osaka, Kansai, this program aims to transform these connections from a one-time opportunity into continuous collaboration. Through Nakanoshima Qross, we seek to foster an international life science innovation ecosystem and investment community that connects startups, investors, corporations, research institutions, and global innovation hubs. The program will feature three events. In addition to introducing activities and initiatives by overseas life science clusters, VCs, and CVCs, promising Japanese startups and US startups will deliver pitches designed to facilitate new business matching and international collaboration among investors, corporations, and startups. Who Should Attend Life science and healthcare startups VCs, CVCs, investors, and corporate investors Companies in pharmaceuticals, medical devices, diagnostics, regenerative medicine, biomanufacturing, and digital health Universities, research institutions, and healthcare organizations Overseas life science clusters, accelerators, and support organizations Companies and organizations interested in collaboration with startups, investment, joint research, business development, and international expansion Timeline 4:30 PM: Opening 4:35 PM: Presentation on the Nakanoshima Cross Project Risa Taniguchi / Project Manager of CIC Tokyo 4:40 PM: Presentation on Overseas Life Sciences Business and Investment Trends Tetsu Yung, PhD MBA / TETSUNAGI Consulting Inc. Founder & CEO 4:55 PM: Pitch Misook Chu MORPHEUS Inc. CEOFounder Atsuhiro Ishii / PtBio Inc. Chief Operating Office Andy Kadlec, M.D., Ph.D. / Founder and CEO of Ten Bay Bio Christopher P Locher, Ph.D. / Co-founder and CEO of Versatope Therapeutics, Inc. Chris Hopkins,…
